CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 242 enrolled
Drug / intervention
biphasic insulin aspart +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00598793
NCT00598793Phase 3Completed
CompareCT.gov

Biphasic Insulin Aspart 70/30 + Metformin Compared to Insulin Glargine + Metformin in Type 2 Diabetes Failing OAD Therapy

Novo Nordisk A/S·interventional·Posted Jan 23, 2008·Updated Jan 9, 2017

In Brief

A Phase 3 clinical trial evaluating biphasic insulin aspart, insulin glargine, and 2 other interventions for Diabetes and Diabetes Mellitus, Type 2. Completed, enrolled 242 participants across 27 sites.

Detailed Summary

This trial is conducted in the United States of America (USA). The aim of this trial is to compare biphasic insulin aspart 30 plus metformin in a standard injection regimen to a standard dosing of insulin glargine plus metformin on blood glucose control in subjects with type 2 diabetes who are insulin naive and failing OAD therapy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes, Diabetes Mellitus, Type 2
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 23, 2008
Enrollment StartNov 1, 2002
Primary CompletionMar 1, 2004
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 18.4 years ago

Interventions

biphasic insulin aspartdrug

insulin glarginedrug

metformindrug

pioglitazonedrug